Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
Saved in:
| Title: | Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. |
|---|---|
| Authors: | Mansfield AS; Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Mansfield.aaron@mayo.edu., Wei Z; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA., Mehra R; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA., Shaw AT; Massachusetts General Hospital, Boston, MA, USA., Lieu CH; University of Colorado Cancer Center, Aurora, CO, USA., Forde PM; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Drilon AE; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, PA, USA., Wright JJ; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Takebe N; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Hovelson D; Strata Oncology, Inc, Ann Arbor, MI, USA., Tomlins S; Strata Oncology, Inc, Ann Arbor, MI, USA., Zeng J; Caris Life Sciences, Irving, TX, USA., Poorman K; Caris Life Sciences, Irving, TX, USA., Malik N; Tempus, Chicago, IL, USA., Gray RJ; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA., Li S; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Patton D; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD, USA., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Hamilton SR; City of Hope, Duarte, CA, USA., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Arteaga CL; Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA, USA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Flaherty KT; Massachusetts General Hospital, Boston, MA, USA. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2022 Mar 01; Vol. 6 (1), pp. 13. Date of Electronic Publication: 2022 Mar 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2397-768X |
|---|---|
| DOI: | 10.1038/s41698-022-00256-w |
